“…The human MBP gene (gene symbol -MBL) has been localized to lOqll.2-q21 (Sastry et ai., 1989), and the human SP-A gene(s) (gene symbol SFTP 1) have been localized to lOq21-q24 (Fisher et al, 1987). There appear to be at least 2 SP-A genes (SP-AI and SP-AII; White et al, 1985;Floros et al, 1986;Katyal et al, 1992) and 1 SP-A pseudogene (Korfhagen et al, 1991) It has been established that, in humans, a low serum concentration of MBP correlates with a common opsonic defect (Super et al,, 1989) and that deficiency of MBP is associated with recurrent infections in the very young (Turner, 1991). It is considered that low serum levels or lack of MBP results in an inability to activate the classical pathway of complement (via MASP or Clr2Clsz), by an antibody-independent route, and this prevents efficient coating of pathogenic organisms with the activated C4 and C3 fragments that are required for efficient opsonization by cells carrying C4b and/or C3b receptors.…”